Telix Pharmaceuticals Limited (NASDAQ:TLX) Sees Significant Increase in Short Interest

Telix Pharmaceuticals Limited (NASDAQ:TLX) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 297,140 shares, an increase of 82.7% from the June 30th total of 162,625 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 165,030 shares, the short-interest ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

TLX has been the subject of several research analyst reports. Citigroup dropped their price target on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the second quarter valued at about $1,731,000. Bank of America Corp DE increased its stake in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. Lazard Asset Management LLC increased its position in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. XY Capital Ltd bought a new position in Telix Pharmaceuticals during the first quarter valued at approximately $120,000. Finally, Private Advisor Group LLC lifted its stake in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the last quarter.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $9.89 on Friday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $14.27. The firm’s 50 day moving average is $10.34 and its two-hundred day moving average is $9.25. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.